Page 30 - Read Online
P. 30

Page 18 of 22         Ballestri et al. Metab Target Organ Damage 2023;3:1  https://dx.doi.org/10.20517/mtod.2022.23

               Ethical approval and consent to participate
               Not applicable.


               Consent for publication
               Not applicable.


               Copyright
               © The Author(s) 2023.


               REFERENCES
               1.       Parola M, Pinzani M. Liver fibrosis: Pathophysiology, pathogenetic targets and clinical issues. Mol Aspects Med 2019;65:37-55.  DOI
                    PubMed
               2.       Lambrecht J, van Grunsven LA, Tacke F. Current and emerging pharmacotherapeutic interventions for the treatment of liver fibrosis.
                    Expert Opin Pharmacother 2020;21:1637-50.  DOI  PubMed
               3.       Friedman SL, Pinzani M. Hepatic fibrosis 2022: Unmet needs and a blueprint for the future. Hepatology 2022;75:473-88.  DOI
                    PubMed
               4.       Gordon SC, Kachru N, Parker E, Korrer S, Ozbay AB, Wong RJ. Health care use and costs among patients with nonalcoholic
                    steatohepatitis with advanced fibrosis using the fibrosis-4 score. Hepatol Commun 2020;4:998-1011.  DOI  PubMed  PMC
               5.       Tacke F, Weiskirchen R. Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis:
                    mechanisms, treatment and prevention. Ann Transl Med 2021;9:729.  DOI  PubMed  PMC
               6.       Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat
                    Med 2018;24:908-22.  DOI  PubMed  PMC
               7.       Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. Lancet 2014;383:1749-61.  DOI
               8.       Dulai PS, Singh S, Patel J, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and
                    meta-analysis. Hepatology 2017;65:1557-65.  DOI
               9.       Sanyal AJ, Van Natta ML, Clark J, et al. Prospective study of outcomes in adults with nonalcoholic fatty liver disease. N Engl J Med
                    2021;385:1559-69.  DOI  PubMed  PMC
               10.       Loomba  R,  Friedman  SL,  Shulman  GI.  Mechanisms  and  disease  consequences  of  nonalcoholic  fatty  liver  disease.  Cell
                    2021;184:2537-64.  DOI  PubMed
               11.       Vilar-Gomez E, Calzadilla-Bertot L, Wai-Sun Wong V, et al. Fibrosis severity as a determinant of cause-specific mortality in patients
                    with advanced nonalcoholic fatty liver disease: a multi-national cohort study. Gastroenterology 2018;155:443-457.e17.  DOI
                    PubMed
               12.       Mantovani A, Csermely A, Petracca G, et al. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an
                    updated systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2021;6:903-13.  DOI  PubMed
               13.       Sumida Y, Nakajima A, Itoh Y. Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty
                    liver disease/nonalcoholic steatohepatitis. World J Gastroenterol 2014;20:475-85.  DOI  PubMed  PMC
               14.       Lonardo A, Ballestri S. Perspectives of nonalcoholic fatty liver disease research: a personal point of view. Explor Med 2020;1:85-
                    107.  DOI
               15.       Wang FD, Zhou J, Chen EQ. Molecular mechanisms and potential new therapeutic drugs for liver fibrosis. Front Pharmacol
                    2022;13:787748.  DOI  PubMed  PMC
               16.       Qu W, Ma T, Cai J, et al. Liver fibrosis and MAFLD: from molecular aspects to novel pharmacological strategies. Front Med
                    (Lausanne) 2021;8:761538.  DOI  PMC
               17.       Bitto N, Liguori E, La Mura V. Coagulation, microenvironment and liver fibrosis. Cells 2018;7:85.  DOI  PubMed  PMC
               18.       Ballestri S, Capitelli M, Fontana MC, et al. Direct oral anticoagulants in patients with liver disease in the era of non-alcoholic fatty
                    liver disease global epidemic: a narrative review. Adv Ther 2020;37:1910-32.  DOI  PubMed  PMC
               19.       Davis  JPE,  Caldwell  SH.  Healing  gone  wrong:  convergence  of  hemostatic  pathways  and  liver  fibrosis?  Clin  Sci  (Lond)
                    2020;134:2189-201.  DOI  PubMed
               20.       Mahmoud NI, Messiha BAS, Salehc IG, Abo-Saif AA, Abdel-Bakky MS. Interruption of platelets and thrombin function as a new
                    approach against liver fibrosis induced experimentally in rats. Life Sci 2019;231:116522.  DOI  PubMed
               21.       Czajka P, Przybyłkowski A, Nowak A, et al. Antiplatelet drugs and liver fibrosis. Platelets 2022;33:219-28.  DOI  PubMed
               22.       Rahman SR, Roper JA, Grove JI, Aithal GP, Pun KT, Bennett AJ. Integrins as a drug target in liver fibrosis. Liver Int 2022;42:507-
                    21.  DOI  PubMed
               23.       Dwyer BJ, Macmillan MT, Brennan PN, Forbes SJ. Cell therapy for advanced liver diseases: repair or rebuild. J Hepatol
                    2021;74:185-99.  DOI  PubMed
               24.       Wang S, Friedman SL. Hepatic fibrosis: a convergent response to liver injury that is reversible. J Hepatol 2020;73:210-1.  DOI
                    PubMed
               25.       Aminian A, Al-Kurd A, Wilson R, et al. Association of bariatric surgery with major adverse liver and cardiovascular outcomes in
   25   26   27   28   29   30   31   32   33   34   35